COVID-19 in a designated infectious diseases hospital outside Hubei Province, China

Allergy. 2020 Jul;75(7):1742-1752. doi: 10.1111/all.14309. Epub 2020 Apr 17.

Abstract

Background: The clinical characteristics of novel coronavirus disease (COVID-2019) patients outside the epicenter of Hubei Province are less understood.

Methods: We analyzed the epidemiological and clinical features of all COVID-2019 cases in the only referral hospital in Shenzhen City, China, from January 11, 2020, to February 6, 2020, and followed until March 6, 2020.

Results: Among the 298 confirmed cases, 233 (81.5%) had been to Hubei, while 42 (14%) did not have a clear travel history. Only 218 (73.15%) cases had a fever as the initial symptom. Compared with the nonsevere cases, severe cases were associated with older age, those with underlying diseases, and higher levels of C-reactive protein, interleukin-6, and erythrocyte sedimentation rate. Slower clearance of the virus was associated with a higher risk of progression to critical condition. As of March 6, 2020, 268 (89.9%) patients were discharged and the overall case fatality ratio was 1.0%.

Conclusions: In a designated hospital outside Hubei Province, COVID-2019 patients could be effectively managed by properly using the existing hospital system. Mortality may be lowered when cases are relatively mild, and there are sufficient medical resources to care and treat the disease.

Keywords: corona Virus Disease 2019; epidemiological features; severe acute respiratory syndrome coronavirus 2; severe pneumonia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Antiviral Agents / therapeutic use
  • Betacoronavirus / genetics*
  • Blood Sedimentation
  • C-Reactive Protein / analysis
  • COVID-19
  • COVID-19 Drug Treatment
  • Child
  • China / epidemiology
  • Coronavirus Infections / blood
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / physiopathology*
  • Female
  • Hospitalization
  • Humans
  • Interleukin-6 / blood
  • Male
  • Middle Aged
  • Pandemics
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / physiopathology*
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2
  • Treatment Outcome
  • Young Adult

Substances

  • Antiviral Agents
  • IL6 protein, human
  • Interleukin-6
  • C-Reactive Protein